OVERVIEW

Aflibercept (Eylea) anti-VEGF intravitreal injection is a prescription eye treatment used to control abnormal blood vessel growth and leakage inside the retina. Doctors use it to manage several sight-threatening retinal diseases. The medicine works by blocking vascular endothelial growth factor (VEGF), a signal protein that causes swelling and fragile new vessels. As a result, retinal fluid decreases and vision often stabilizes or improves.

COMMON INDICATIONS

Your ophthalmologist may recommend Aflibercept (Eylea) injection for the following conditions:

1. Wet age-related macular degeneration
2. Diabetic macular edema
3. Macular edema after retinal vein occlusion
4. Myopic choroidal neovascularization

Early treatment matters. Therefore, prompt diagnosis and timely injections help protect central vision.

HOW THE TREATMENT WORKS

Aflibercept binds VEGF inside the eye and prevents it from triggering leakage and abnormal vessel formation. Consequently, retinal swelling reduces and oxygen balance improves. Many patients notice clearer or more stable vision after a loading series, followed by spaced maintenance doses. However, response varies by disease severity and treatment timing.

HOW THE PROCEDURE IS DONE

The injection takes place in a sterile clinic or operating room setting. First, the eye is cleaned and numbed with anesthetic drops. Next, the ophthalmologist delivers a very small measured dose into the vitreous cavity using a fine needle. The procedure usually lasts only a few minutes. Most patients feel pressure but not sharp pain. Afterward, you can usually go home the same day.

EXPECTED BENEFITS

Clinical studies show that anti-VEGF therapy with Aflibercept can maintain or improve vision in many patients when given on schedule. In addition, regular monitoring with retinal scans guides dose timing. Because retinal diseases are often chronic, repeated treatments are commonly required for best results.

POSSIBLE SIDE EFFECTS AND RISKS

Most side effects are mild and temporary. These may include eye redness, irritation, tearing, or small floaters. However, rare but serious risks can occur, such as infection inside the eye, retinal tear, retinal detachment, increased eye pressure, bleeding, or inflammation. Therefore, immediate consultation is required if you notice severe pain, marked redness, sudden vision loss, or increasing light sensitivity after injection.

WHO SHOULD NOT RECEIVE THE INJECTION

This treatment is not given when active eye infection or severe ocular inflammation is present. Also, your doctor will review allergies, pregnancy status, and overall health before treatment.

AFTERCARE AND FOLLOW-UP

After the injection, avoid rubbing the eye and keep it clean. Mild scratchy sensation can occur for one to two days. Use prescribed drops if advised. Moreover, attend all scheduled follow-up visits because treatment intervals are personalized. Consistent follow-up improves safety and visual outcomes.

IMPORTANT NOTE

This product description supports patient education but does not replace a full medical consultation. Treatment decisions depend on detailed retinal evaluation and specialist advice.